Nouscom’s Neoantigen Vaccine Synergizes with NKTR-214 to Cure Established Tumors in Preclinical Model

Basel, Switzerland – 13 November 2017 Nouscom, an oncology company developing next generation cancer vaccines based on its Exovax platform, today announced preclinical data of its neoantigen [...]

Nouscom raises €42 million Series B financing led by new investor Abingworth with participation from 5AM Ventures, LSP and Versant Ventures

Basel, Switzerland – 6 November 2017 Nouscom, an oncology company developing neoantigen cancer vaccines based on its Exovax platform, today announced the completion of a €42 million Series B [...]